Branded Generics Market : TOC


Branded Generics Market

Branded Generics Market: Oncology Therapeutic Application Segment Expected to Grow Significantly in Developed Markets over the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016 –2026

  • REP-GB-1260
  • 2017-01-13
  • 222 Pages
  • Format: pdf ppt
  • Category: Healthcare, Pharmaceuticals and Medical devices

Table Of Content

1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

2.3. Generics Market Overview

3. Global Branded Generics Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

3.2. Market Overview

3.2.1. Value Chain

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Forecast Factors – Relevance and Impact

4.7.Regulations

4.8.Porter Five Forces Model

4.9.Patennt expiries in 2016

5. Global Branded Generics Market Analysis and Forecasts, By Therapeutic Application Type 

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Therapeutic Application Type

5.3. Y-o-Y Growth Projections By Therapeutic Application Type

5.4. Market Value Forecast By Therapeutic Application Type , 2016–2026

5.4.1. Oncology

5.4.2. Cardiovascular Diseases

5.4.3. Diabetes

5.4.4. Neurology

5.4.5. Gastrointestinal Diseases

5.4.6. Dermatology Diseases

5.4.7. Analgesics and Anti-inflammatory

5.4.8. Others

5.5. Prominent Trends

5.6. Market Attractiveness By Therapeutic Application Type 

6. Global Branded Generics Market Analysis and Forecasts, By Distribution Channel 

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By Distribution Channel 

6.3. Y-o-Y Growth Projections By Distribution Channel 

6.4. Market Value Forecast By Distribution Channel, 2016–2026

6.4.1. Hospital Pharmacies

6.4.2. Retail Pharmacies

6.4.3. Online Pharmacies

6.4.4. Drug Stores

6.5. Prominent Trends

6.6. Market Attractiveness By Distribution Channel 

7. Global Branded Generics Market Analysis and Forecasts, By Major Drug Classes

7.1. Introduction

7.2. Basis Point Share (BPS) Analysis By Major Drug Classes

7.3. Y-o-Y Growth Projections By Major Drug Classes

7.4. Market Value Forecast By Major Drug Classes, 2016–2026

7.4.1. Alkylating Agents

7.4.2. Antimetabolites

7.4.3. Hormones

7.4.4. Anti-Hypertensive

7.4.5. Lipid Lowering Drugs

7.4.6. Anti-Depressants

7.4.7. Anti-Psychotics

7.4.8. Anti-Epileptic

7.4.9. Others

7.5. Prominent Trends

7.6. Market Attractiveness By Major Drug Classes

8. Global Branded Generics Market Analysis and Forecasts, By Formulation Type 

8.1. Introduction

8.2. Basis Point Share (BPS) Analysis By Formulation Type 

8.3. Y-o-Y Growth Projections By Formulation Type 

8.4. Market Value Forecast By Formulation Type , 2016–2026

8.4.1. Oral 

8.4.2. Parenteral 

8.4.3. Topical 

8.4.4. Others

8.5. Prominent Trends

8.6. Market Attractiveness By Formulation Type 

9. Global Branded Generics Market Analysis and Forecasts, By Region

9.1. Basis Point Share (BPS) Analysis By Region

9.2. Y-o-Y Growth Projections By Region

9.3. Market Value Forecast By Region

9.3.1. North America 

9.3.2. Latin America 

9.3.3. Western Europe 

9.3.4. Eastern Europe 

9.3.5. APEJ 

9.3.6. Japan 

9.3.7. MEA 

9.4. Market Attractiveness By Region

10. North America Branded Generics Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.1.3. Key Regulations

10.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

10.2.1. Oncology

10.2.2. Cardiovascular Diseases

10.2.3. Diabetes

10.2.4. Neurology

10.2.5. Gastrointestinal Diseases

10.2.6. Dermatology Diseases

10.2.7. Analgesics and Anti-inflammatory

10.2.8. Others

10.3.Market Value Forecast By Distribution Channel, 2016–2026

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.3.4. Drug Stores

10.4.Market Value Forecast By Major Drug Classes, 2016–2026

10.4.1. Alkylating Agents

10.4.2. Antimetabolites

10.4.3. Hormones

10.4.4. Anti-Hypertensive

10.4.5. Lipid Lowering Drugs

10.4.6. Anti-Depressants

10.4.7. Anti-Psychotics

10.4.8. Anti-Epileptic

10.4.9. Others

10.5.Market Value Forecast By Formulation Type , 2016–2026

10.5.1. Oral 

10.5.2. Parenteral 

10.5.3. Topical 

10.5.4. Others

10.6.Market Value Forecast By Country, 2016–2026

10.6.1. US

10.6.2. Canada

10.7.Market Attractiveness Analysis 

10.7.1. By Therapeutic Application Type 

10.7.2. By Distribution Channel 

10.7.3. By Major Drug Classes

10.7.4. By Formulation Type 

10.7.5. By Country

10.8. Prominent Trends 

10.9. Drivers and Restraints: Impact Analysis 

11. Latin America Branded Generics Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

11.2.1. Oncology

11.2.2. Cardiovascular Diseases

11.2.3. Diabetes

11.2.4. Neurology

11.2.5. Gastrointestinal Diseases

11.2.6. Dermatology Diseases

11.2.7. Analgesics and Anti-inflammatory

11.2.8. Others

11.3.Market Value Forecast By Distribution Channel, 2016–2026

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.3.4. Drug Stores

11.4.Market Value Forecast By Major Drug Classes, 2016–2026

11.4.1. Alkylating Agents

11.4.2. Antimetabolites

11.4.3. Hormones

11.4.4. Anti-Hypertensive

11.4.5. Lipid Lowering Drugs

11.4.6. Anti-Depressants

11.4.7. Anti-Psychotics

11.4.8. Anti-Epileptic

11.4.9. Others

11.5.Market Value Forecast By Formulation Type , 2016–2026

11.5.1. Oral 

11.5.2. Parenteral 

11.5.3. Topical 

11.5.4. Others

11.6.Market Value Forecast By Country, 2016–2026

11.6.1. Argentina

11.6.2. Brazil

11.6.3. Mexico

11.6.4. Rest of Latin America

11.7.Market Attractiveness Analysis 

11.7.1. By Therapeutic Application Type 

11.7.2. By Distribution Channel 

11.7.3. By Major Drug Classes

11.7.4. By Formulation Type 

11.7.5. By Country

11.8. Prominent Trends 

11.9. Drivers and Restraints: Impact Analysis 

12. Western Europe Branded Generics Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.1.3. Key Regulations

12.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

12.2.1. Oncology

12.2.2. Cardiovascular Diseases

12.2.3. Diabetes

12.2.4. Neurology

12.2.5. Gastrointestinal Diseases

12.2.6. Dermatology Diseases

12.2.7. Analgesics and Anti-inflammatory

12.2.8. Others

12.3.Market Value Forecast By Distribution Channel, 2016–2026

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.3.4. Drug Stores

12.4.Market Value Forecast By Major Drug Classes, 2016–2026

12.4.1. Alkylating Agents

12..4.2. Antimetabolites

12.4.3. Hormones

12.4.4. Anti-Hypertensive

12.4.5. Lipid Lowering Drugs

12.4.6. Anti-Depressants

12.4.7. Anti-Psychotics

12.4.8. Anti-Epileptic

12.4.9. Others

12.5.Market Value Forecast By Formulation Type , 2016–2026

12.5.1. Oral 

12.5.2. Parenteral 

12.5.3. Topical 

12.5.4. Others

12.6.Market Value Forecast By Country, 2016–2026

12.6.1. UK

12.6.2. France

12.6.3. Germany

12.6.4. Italy

12.6.5. Spain

12.6.6. Nordic

12.6.7. Benelux

12.6.8. Rest of Western Europe

12.7.Market Attractiveness Analysis 

12.7.1. By Therapeutic Application Type 

12.7.2. By Distribution Channel 

12.7.3. By Major Drug Classes

12.7.4. By Formulation Type 

12.7.5. By Country

12.8. Prominent Trends 

12.9. Drivers and Restraints: Impact Analysis 

13. Eastern Europe Branded Generics Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.1.3. Key Regulations

13.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

13.2.1. Oncology

13.2.2. Cardiovascular Diseases

13.2.3. Diabetes

13.2.4. Neurology

13.2.5. Gastrointestinal Diseases

13.2.6. Dermatology Diseases

13.2.7. Analgesics and Anti-inflammatory

13.2.8. Others

13.3.Market Value Forecast By Distribution Channel, 2016–2026

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.3.4. Drug Stores

13.4.Market Value Forecast By Major Drug Classes, 2016–2026

13.4.1. Alkylating Agents

13..4.2. Antimetabolites

13.4.3. Hormones

13.4.4. Anti-Hypertensive

13.4.5. Lipid Lowering Drugs

13.4.6. Anti-Depressants

13.4.7. Anti-Psychotics

13.4.8. Anti-Epileptic

13.4.9. Others

13.5.Market Value Forecast By Formulation Type , 2016–2026

13.5.1. Oral 

13.5.2. Parenteral 

13.5.3. Topical 

13.5.4. Others

13.6.Market Value Forecast By Country, 2016–2026

13.6.1. Russia

13.6.2. Poland

13.6.3. Rest of Eastern Europe

13.7.Market Attractiveness Analysis 

13.7.1. By Therapeutic Application Type 

13.7.2. By Distribution Channel 

13.7.3. By Major Drug Classes

13.7.4. By Formulation Type 

13.7.5. By Country

13.8. Prominent Trends 

13.9. Drivers and Restraints: Impact Analysis 

14. APEJ Branded Generics Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

14.2.1. Oncology

14.2.2. Cardiovascular Diseases

14.2.3. Diabetes

14.2.4. Neurology

14.2.5. Gastrointestinal Diseases

14.2.6. Dermatology Diseases

14.2.7. Analgesics and Anti-inflammatory

14.2.8. Others

14.3.Market Value Forecast By Distribution Channel, 2016–2026

14.3.1. Hospital Pharmacies

14.3.2. Retail Pharmacies

14.3.3. Online Pharmacies

14.3.4. Drug Stores

14.4.Market Value Forecast By Major Drug Classes, 2016–2026

14.4.1. Alkylating Agents

14..4.2. Antimetabolites

14.4.3. Hormones

14.4.4. Anti-Hypertensive

14.4.5. Lipid Lowering Drugs

14.4.6. Anti-Depressants

14.4.7. Anti-Psychotics

14.4.8. Anti-Epileptic

14.4.9. Others

14.5.Market Value Forecast By Formulation Type , 2016–2026

14.5.1. Oral 

14.5.2. Parenteral 

14.5.3. Topical 

14.5.4. Others

14.6.Market Value Forecast By Country, 2016–2026

14.6.1. China

14.6.2. India

14.6.3. Australia & New Zealand

14.6.4. ASEAN

14.6.5. Rest of APEJ

14.7.Market Attractiveness Analysis 

14.7.1. By Therapeutic Application Type 

14.7.2. By Distribution Channel 

14.7.3. By Major Drug Classes

14.7.4. By Formulation Type 

14.7.5. By Country

14.8. Prominent Trends 

14.9. Drivers and Restraints: Impact Analysis 

15. Japan Branded Generics Market Analysis and Forecast

15.1.Introduction

15.1.1. Basis Point Share (BPS) Analysis By Country

15.1.2. Y-o-Y Growth Projections By Country

15.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

15.2.1. Oncology

15.2.2. Cardiovascular Diseases

15.2.3. Diabetes

15.2.4. Neurology

15.2.5. Gastrointestinal Diseases

15.2.6. Dermatology Diseases

15.2.7. Analgesics and Anti-inflammatory

15.2.8. Others

15.3.Market Value Forecast By Distribution Channel, 2016–2026

15.3.1. Hospital Pharmacies

15.3.2. Retail Pharmacies

15.3.3. Online Pharmacies

15.3.4. Drug Stores

15.4.Market Value Forecast By Major Drug Classes, 2016–2026

15.4.1. Alkylating Agents

15..4.2. Antimetabolites

15.4.3. Hormones

15.4.4. Anti-Hypertensive

15.4.5. Lipid Lowering Drugs

15.4.6. Anti-Depressants

15.4.7. Anti-Psychotics

15.4.8. Anti-Epileptic

15.4.9. Others

15.5.Market Value Forecast By Formulation Type , 2016–2026

15.5.1. Oral 

15.5.2. Parenteral 

15.5.3. Topical 

15.5.4. Others

15.6.Market Attractiveness Analysis 

15.6.1. By Therapeutic Application Type 

15.6.2. By Distribution Channel 

15.6.3. By Major Drug Classes

15.6.4. By Formulation Type 

15.7. Prominent Trends 

15.8. Drivers and Restraints: Impact Analysis 

16. MEA Branded Generics Market Analysis and Forecast

16.1.Introduction

16.1.1. Basis Point Share (BPS) Analysis By Country

16.1.2. Y-o-Y Growth Projections By Country

16.2.Market Value Forecast By Therapeutic Application Type , 2016–2026

16.2.1. Oncology

16.2.2. Cardiovascular Diseases

16.2.3. Diabetes

16.2.4. Neurology

16.2.5. Gastrointestinal Diseases

16.2.6. Dermatology Diseases

16.2.7. Analgesics and Anti-inflammatory

16.2.8. Others

16.3.Market Value Forecast By Distribution Channel, 2016–2026

16.3.1. Hospital Pharmacies

16.3.2. Retail Pharmacies

16.3.3. Online Pharmacies

16.3.4. Drug Stores

16.4.Market Value Forecast By Major Drug Classes, 2016–2026

16.4.1. Alkylating Agents

16..4.2. Antimetabolites

16.4.3. Hormones

16.4.4. Anti-Hypertensive

16.4.5. Lipid Lowering Drugs

16.4.6. Anti-Depressants

16.4.7. Anti-Psychotics

16.4.8. Anti-Epileptic

16.4.9. Others

16.5.Market Value Forecast By Formulation Type , 2016–2026

16.5.1. Oral 

16.5.2. Parenteral 

16.5.3. Topical 

16.5.4. Others

16.6.Market Value Forecast By Country, 2016–2026

16.6.1. GCC Countries

16.6.2. South Africa

16.6.3. North Africa

16.6.4. Rest of MEA

16.7.Market Attractiveness Analysis 

16.7.1. By Therapeutic Application Type 

16.7.2. By Distribution Channel 

16.7.3. By Major Drug Classes

16.7.4. By Formulation Type 

16.7.5. By Country

16.8. Prominent Trends 

16.9. Drivers and Restraints: Impact Analysis 

17. Competition Landscape

17.1. Competition Dashboard

17.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

17.2.1. Mylan N.V

17.2.2. Novartis AG

17.2.3. Teva Pharmaceutical Industries Ltd

17.2.4. Pfizer Inc.

17.2.5. Sun Pharmaceutical Industries Ltd.

17.2.6. Aspen Pharmacare Holding Ltd.

17.2.7. Abbott Laboratories

17.2.8. Valeant Pharmaceuticals International, Inc.

18. Assumptions and Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 2: Global Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 3: Global Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 4: Global Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 5: Global Branded Generics Market Value (US$ Bn) Analysis and Forecast By Region, 2015–2026

Table 6: North America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 7: North America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 8: North America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 9: North America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 10: North America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 11: Latin America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 12: Latin America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026i

Table 13: Latin America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 14: Latin America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 15: Latin America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 16: Western Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 17: Western Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 18: Western Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 19: Western Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 20: Western Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 21: Eastern Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 22: Eastern Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 23: Eastern Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 24: Eastern America Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 25: Eastern Europe Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 26: APEJ Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 27: APEJ Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 28: APEJ Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 29: APEJ Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 30: APEJ Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 31: Japan Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 32: Japan Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 33: Japan Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 34: Japan Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

Table 35: MEA Branded Generics Market Value (US$ Bn) Analysis and Forecast By Country, 2015–2026

Table 36: MEA Branded Generics Market Value (US$ Bn) Analysis and Forecast By Therapeutic Application, 2015 – 2026

Table 37: MEA Branded Generics Market Value (US$ Bn) Analysis and Forecast By Drug Class, 2015 – 2026

Table 38: MEA Branded Generics Market Value (US$ Bn) Analysis and Forecast By Formulation Type, 2015 – 2026

Table 39: MEA Branded Generics Market Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2015–2026

List of Figures

Figure 01: Global Branded Generics Market Value Share By, Therapeutic Application, 2016

Figure 02: Global Branded Generics Market Value Share By, Formulation Type, 2016

Figure 03: Global Branded Generics Market Value Share By, Distribution Channel, 2016

Figure 04: Global Branded Generics Market Value Share By, Region, 2016

Figure 05: Global Branded Generics Market Value (US$ Bn) Forecast, 2015–2026 

Figure 06: Global Branded Generics Market Absolute $ Opportunity, 2015–2026 

Figure 07: Global Branded Generics Market Y-o-Y Growth, 2015–2026 

Figure 8: Global Branded Generics Market Share Analysis (%) By Therapeutic Application, 2016 & 2026

Figure 9: Global Branded Generics Market Y-o-Y Growth (%) By Therapeutic Application, 2015–2026 

Figure 10: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Oncology Segment, 2015 – 2026

Figure 11: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2015 – 2026

Figure 12: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Diabetes Segment, 2015 – 2026

Figure 13: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Neurology Segment, 2015 – 2026

Figure 14: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Gastrointestinal Diseases Segment, 2015 – 2026

Figure 15: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Dermatology Diseases Segment, 2015 – 2026

Figure 16: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Analgesics and Anti-inflammatory Segment, 2015 – 2026

Figure 17: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Others Segment, 2015 – 2026

Figure 18: Global Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016–2026 

Figure 19: Global Branded Generics Market Share Analysis (%) By Drug Class, 2020 & 2026

Figure 20: Global Branded Generics Market Y-o-Y Growth (%) By Drug Class, 2015–2026 

Figure 21: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Alkylating Agents Segment, 2015 – 2026

Figure 22: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Antimetabolites Segment, 2015 – 2026

Figure 23: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Hormones Segment, 2015 – 2026

Figure 24: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Anti-Hypertensive  Segment, 2015 – 2026

Figure 25: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Lipid Lowering Drugs Segment, 2015 – 2026

Figure 26: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Anti-Depressants Segment, 2015 – 2026

Figure 27: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Anti-Psychotics Segment, 2015 – 2026

Figure 28: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Anti-Epileptics Segment, 2015 – 2026

Figure 29: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Others Segment, 2015 – 2026

Figure 30: Global Branded Generics Market Attractiveness Analysis By Drug Class, 2016–2026 

Figure 31: Global Branded Generics Market Share Analysis (%) By Formulation Type, 2020 & 2026

Figure 32: Global Branded Generics Market Y-o-Y Growth (%) By Formulation Type, 2015–2026 

Figure 33: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Oral Segment, 2015 – 2026

Figure 34: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Parenteral Segment, 2015 – 2026

Figure 35: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Topical

Figure 36: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Others Segment, 2015 – 2026

Figure 37: Global Branded Generics Market Attractiveness Analysis By Formulation Type, 2016–2026 

Figure 38: Global Branded Generics Market Share Analysis (%) By Distribution Channel, 2016, 2026

Figure 39: Global Branded Generics Market Y-o-Y Growth (%) By Distribution Channel, 2015–2026 

Figure 40: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Hospital Pharmacies Segment, 2015 – 2026

Figure 41: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Retail Pharmacies Segment, 2015 – 2026

Figure 42: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Online Pharmacies Segment, 2015 – 2026

Figure 43: Global Branded Generics Market Absolute $ Opportunity (US$ Bn) By Drug Stores Segment, 2015 – 2026

Figure 44: Global Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016–2026 

Figure 45: Global Branded Generics Market Share Analysis (%) By Region, 2016, 2026

Figure 46: Global Branded Generics Market Y-o-Y Growth (%) By Region, 2015–2026 

Figure 47: North America Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 48: Latin America Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 49: Western Europe Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 50: Eastern Europe Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 51: APEJ Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 52: Japan Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 53: MEA Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 54: Global Branded Generics Market Attractiveness Analysis By Region, 2016–2026 

Figure 55: North America Branded Generics Market Share Analysis (%) By Country, 2016, 2026

Figure 56: North America Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 57: The U.S. Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 58: Canada Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 59: North America Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 60: North America Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 61: North America Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 62: North America Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 63: North America Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 64: Latin America Branded Generics Market Share Analysis (%) By Country, 2016, 2020 & 2026

Figure 65: Latin America Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 66: Mexico Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 67: Brazil Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 68: Argentina Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 69: Rest of Latin America

Figure 70: Latin America Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 71: Latin America Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 72: Latin America Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 73: Latin America Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 74: Latin America Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 75: Western Europe Branded Generics Market Share Analysis (%) By Country, 2016, 2026

Figure 76: Western Europe Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 77: Germany Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 78: France Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 79: The U.K. Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 80: Spain Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 81: Italy Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 82: Nordic Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 83: BENELUX Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 84: Rest of Western Europe Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 85: Western Europe Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 86: Western Europe Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 87: Western Europe Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 88: Western Europe Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 89: Western Europe Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 90: Eastern Europe Branded Generics Market Share Analysis (%) By Country, 2016, 2026

Figure 91: Eastern Europe Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 92: Russia Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 93: Poland Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 94: Rest of Eastern Europe Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 95: Eastern Europe Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 96: Eastern Europe Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 97: Eastern Europe Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 98: Eastern Europe Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 99: Eastern Europe Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 100: APEJ Branded Generics Market Share Analysis (%) By Country, 2016,  2026

Figure 101: APEJ Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 102: China Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 103: India Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 104: ASEAN Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 105: A&NZ Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 106: Rest of APEJ Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 107: APEJ Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 108: APEJ Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 109: APEJ Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 110: APEJ Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 111: APEJ Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 112: Japan Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 113: Japan Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 114: Japan Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026 

Figure 115: Japan Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 116: MEA Branded Generics Market Share Analysis (%) By Country, 2016, 2026

Figure 117: MEA Branded Generics Market Y-o-Y Growth (%) By Country, 2015–2026 

Figure 118: GCC countries Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 119: South Africa Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 120: North Africa Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 121: Rest of MEA Branded Generics Market Absolute $ Opportunity (US$ Bn), 2015 – 2026

Figure 122: MEA Branded Generics Market Attractiveness Analysis By Country, 2016 – 2026 

Figure 123: MEA Branded Generics Market Attractiveness Analysis By Therapeutic Application, 2016 – 2026 

Figure 125: MEA Branded Generics Market Attractiveness Analysis By Formulation Type, 2016 – 2026 

Figure 124: MEA Branded Generics Market Attractiveness Analysis By Drug Class, 2016 – 2026 

Figure 126: MEA Branded Generics Market Attractiveness Analysis By Distribution Channel, 2016 – 2026